GSK's HIV franchise could reach £7B in 2026, analyst says, as real-world data start backing long-acting Cabenuva
21st October 2022 Uncategorised 0 GSK’s HIV franchise could reach £7B in 2026, analyst says, as real-world data start backing long-acting Cabenuva
aliu
Fri, 10/21/2022 – 10:35
More: GSK's HIV franchise could reach £7B in 2026, analyst says, as real-world data start backing long-acting Cabenuva
Source: fierce